Success story - ZAS Biobank

The ZAS Biobank (Campus Augustinus, Antwerp) is supporting a study on targeted and longitudinal sampling to advance research on triple-negative breast cancer (TNBC), a subtype that urgently needs more scientific attention.

🎯 **Project Focus :** Collection of serum, plasma & DNA from TNBC patients receiving neoadjuvant therapy

📅 **Longitudinal Sampling Points :** Baseline (diagnosis), Pre-surgery, Post-surgery, Post-radiotherapy, 4, 8, 12, 24, 36 & 48 months after radiotherapy, Relapse

✓ **Project Implementation**

- Tailored Ethics-approved informed consent
- Harmonized procedures
- Full team training across all steps

📈 **Pilot Progress (Feb 2025 → Jan 2026)**

- 25 patients enrolled
- Well-captured: baseline, pre-surgery, post-surgery & post-radiotherapy
- Target: 30 patients → evaluation upon completion



Evaluation of the pilot will occur once the baseline target of 30 patients is reached. Lessons learned will guide the progression of the "Targeted and Longitudinal Sampling of TNBC Patients" initiative toward completing the collection for 100 patients.

Read more here

BBMRI·be
biobanking for a healthier world